Photo of Lisa C. Silbert, M.D., M.C.R.

Lisa C. Silbert M.D., M.C.R.

Lisa C. Silbert, MD, MCR, FAAN, is an Associate Professor in the Department of Neurology at Oregon Health & Science University School of Medicine, Director of the Neuroimaging Core at the Oregon Aging and Alzheimer's Disease Center, Director of the Dementia Clinic at the VA Portland Health Care System, and a Clinical Research Concentration Lead for the OHSU SOM Scholarly Projects course. She completed her neurology residency at UCLA and fellowship training in both Geriatric Neurology and Clinical Neurophysiology at OHSU. Dr. Silbert's clinical practice consists primarily of patients with neurodegenerative disease affecting cognitive function, and intraoperative neurophysiological monitoring.

Dr. Silbert's research focuses on the effects of cerebral white matter ischemic change on cognitive and motor function in the elderly. Her studies include investigations of how differing rates of white matter damage affect cognition, how changes in cerebral blood flow and microstructural white matter integrity impact expansion of white matter hyperintensity lesions, and the utilization of post-mortem high field MRI for targeted histopathological characterization of small vessel cerebrovascular disease. She has received funding for this work from the Alzheimer's Association, the American Academy of Neurology Foundation, and the NIH/NIA, including a K23/Paul B. Beeson career development award in aging research and an R01.

Read more
  • Residency:

    • University of California, Los Angeles - Neurology Residency
  • Fellowship:

    • Oregon Health & Science University - Clinical Neurophysiology and Geriatric Neurology
  • Certifications:

    • ABPN


  • "Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states." Scientific Reports  In: , Vol. 8, No. 1, 4103, 01.12.2018.
  • "Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time." Neurology  In: , Vol. 90, No. 24, 12.06.2018, p. e2107-e2118.
  • "Progress toward standardized diagnosis of vascular cognitive impairment : Guidelines from the Vascular Impairment of Cognition Classification Consensus Study." Alzheimer's and Dementia  In: , Vol. 14, No. 3, 01.03.2018, p. 280-292.
  • "MR imaging-based multimodal autoidentification of perivascular spaces (mMAPS) : Automated morphologic segmentation of enlarged perivascular spaces at clinical field strength." Radiology  In: , Vol. 286, No. 2, 01.02.2018, p. 632-642.
  • "Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old." Alzheimer Disease and Associated Disorders  In: , 01.01.2018.
  • "Effects of traumatic brain injury on sleep and enlarged perivascular spaces." Journal of Cerebral Blood Flow and Metabolism  In: , 01.01.2018.
  • "Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia." Molecular Neurobiology  In: , 01.01.2018.
  • "Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease." Journal of Alzheimer's Disease  In: , Vol. 66, No. 4, 01.01.2018, p. 1587-1597.
  • "Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic Features." Scientific Reports  In: , Vol. 7, No. 1, 8137, 01.12.2017.
  • "Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty." Scientific Reports  In: , Vol. 7, No. 1, 14052, 01.12.2017.
  • "The Vascular Impairment of Cognition Classification Consensus Study." Alzheimer's and Dementia  In: , Vol. 13, No. 6, 01.06.2017, p. 624-633.
  • "Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease." JAMA Neurology  In: , Vol. 74, No. 5, 01.05.2017, p. 557-566.
  • "Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease." Scientific Reports  In: , Vol. 7, 39880, 12.01.2017.
  • "Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities : A multi-modal magnetic resonance imaging study." Journal of Cerebral Blood Flow and Metabolism  In: , Vol. 36, No. 9, 01.09.2016, p. 1528-1536.
  • "Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults." JAMA Neurology  In: , Vol. 73, No. 6, 01.06.2016, p. 721-732.
  • "Less Daily Computer Use is Related to Smaller Hippocampal Volumes in Cognitively Intact Elderly." Journal of Alzheimer's Disease  In: , Vol. 52, No. 2, 10.05.2016, p. 713-717.
  • "Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease." Alzheimer's and Dementia  In: , 2016.
  • "Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures." NeuroImage: Clinical  In: , Vol. 8, 08.06.2015, p. 224-229.
  • "At the interface of sensory and motor dysfunctions and Alzheimer's disease." Alzheimer's and Dementia  In: , Vol. 11, No. 1, 2015, p. 70-98.
  • "Depressive symptoms are associated with late life cognitive decline independent of common age-related pathologies." Evidence-Based Mental Health  In: , Vol. 18, No. 2, 2015, p. 50.
  • "The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance : Evidence of validity." Alzheimer's and Dementia  In: , Vol. 11, No. 2, 2015, p. 111-125.
  • "Surgery is associated with ventricular enlargement as well as cognitive and functional decline." Alzheimer's and Dementia  In: , 2015.
  • "Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease." Alzheimer's and Dementia  In: , Vol. 10, No. 6, 01.11.2014, p. 690-703.
  • "Role of soluble epoxide hydrolase in age-related vascular cognitive decline." Prostaglandins and Other Lipid Mediators  In: , Vol. 113-115, 30.09.2014, p. 30-37.
  • "TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions." Acta Neuropathologica  In: , Vol. 127, No. 3, 03.2014, p. 407-418.
  • "A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease." Journal of Alzheimer's Disease  In: , Vol. 38, No. 1, 2014, p. 111-120.
  • "Neuropathologic basis of white matter hyperintensity accumulation with advanced age." Neurology  In: , Vol. 81, No. 11, 10.09.2013, p. 977-983.
  • "Neuropathologic basis of age-associated brain atrophy." JAMA Neurology  In: , Vol. 70, No. 5, 2013, p. 616-622.
  • "Plasma omega-3 PUFA and white matter mediated executive decline in older adults." Frontiers in Aging Neuroscience  In: , Vol. 5, No. DEC, Article 92, 2013.
  • "Trajectory of white matter hyperintensity burden preceding mild cognitive impairment." Neurology  In: , Vol. 79, No. 8, 21.08.2012, p. 741-747.

Additional information

Edit profile